{"organizations": [], "uuid": "fce65f1ce93792703597a01193e0af32c535915e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/17/business-wire-mani-foroohar-m-d-joins-leerink-partners-equity-research-team.html", "country": "US", "domain_rank": 767, "title": "Mani Foroohar, M.D. Joins Leerink Partners Equity Research Team", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-17T17:00:00.000+03:00", "replies_count": 0, "uuid": "fce65f1ce93792703597a01193e0af32c535915e"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/17/business-wire-mani-foroohar-m-d-joins-leerink-partners-equity-research-team.html", "ord_in_thread": 0, "title": "Mani Foroohar, M.D. Joins Leerink Partners Equity Research Team", "locations": [], "entities": {"persons": [{"name": "mani foroohar", "sentiment": "negative"}, {"name": "mani", "sentiment": "none"}, {"name": "foroohar", "sentiment": "none"}], "locations": [{"name": "boston", "sentiment": "none"}, {"name": "new york", "sentiment": "none"}, {"name": "columbia", "sentiment": "none"}, {"name": "aptigon", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "leerink partners equity research team", "sentiment": "negative"}, {"name": "leerink partners", "sentiment": "negative"}, {"name": "eu", "sentiment": "none"}, {"name": "department of genetics", "sentiment": "none"}, {"name": "stanford", "sentiment": "none"}, {"name": "citadel company", "sentiment": "none"}, {"name": "ucla", "sentiment": "none"}, {"name": "barclays", "sentiment": "none"}, {"name": "green owl capital management", "sentiment": "none"}, {"name": "equity research", "sentiment": "none"}, {"name": "cellanyx diagnostics", "sentiment": "none"}, {"name": "aptigon capital", "sentiment": "none"}, {"name": "howard hughes medical institute research fellow", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BOSTON--(BUSINESS WIRE)-- Leerink Partners, a leading healthcare investment bank, announced today the hiring of Mani Foroohar, M.D. to the firm’s Equity Research team. Dr. Foroohar will join the firm in May as a Managing Director, Senior Research Analyst within the Therapeutics team and will be located in their New York office.\nDr. Foroohar joins Leerink Partners from Aptigon Capital, a Citadel Company, where he most recently was a Therapeutics Analyst focused on US and EU biotechnology, major pharmaceuticals and specialty pharmaceuticals sectors. Prior to Aptigon, Mani was an Analyst at Green Owl Capital Management and an Assistant Vice President of Equity Research at Barclays. In 2013 Dr. Foroohar co-founded Cellanyx Diagnostics, a company developing a proprietary live tumor cell, phenotypic platform for precision risk stratification in cancer to inform clinical treatment decision making.\nDr. Foroohar holds an M.D. from Stanford, where he was a Howard Hughes Medical Institute Research Fellow in the Department of Genetics, MBA from Columbia, and a B.S. from UCLA.\n“I’m delighted that Mani is joining us at Leerink to cover the growing number of companies developing breakthrough technologies addressing the genetic basis of human disease,” stated John L. Sullivan, CFA, Senior Managing Director of Equity Research at Leerink Partners. “These companies are among the most exciting, volatile and complex in the industry, and Mani’s combined medical training and buy side experience should make him very effective resource for Leerink’s buyside clients.”\nGeoffrey Porges, Senior Biotechnology Analyst and Director of Therapeutics Research at Leerink said, “For the first time in history, the biopharmaceutical industry is on the cusp of altering the genetics of human disease. I’m confident that Mani can offer a unique perspective on the controversies about such medicines to our clients considering investments in companies developing these technologies.”\n“Leerink Partners has established itself as the leader in healthcare equity research and I am excited to work alongside such a strong team of analysts who are committed to delivering deep, differentiated and proprietary research to clients,” stated Dr. Foroohar.\nAbout Leerink Partners\nLeerink Partners LLC is a leading investment bank, specializing in healthcare. Our knowledge, experience and focus enable us to help our clients define and achieve their strategic, capital markets and investment objectives. We partner with companies that develop and commercialize innovative products and services that are defining the future of healthcare. Leerink Partners LLC is a member of FINRA/SIPC. For more information, please visit: www.leerink.com .\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180517005070/en/\nLeerink Partners\nDiane Vieira, 617-918-4097\nor\nWeber Shandwick\n617-520-7088\nSource: Leerink Partners", "external_links": ["https://www.businesswire.com/news/home/20180517005070/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.leerink.com&esheet=51807608&newsitemid=20180517005070&lan=en-US&anchor=www.leerink.com&index=1&md5=fb3ef130f7ebe46cd211886016d94cdf"], "published": "2018-05-17T17:00:00.000+03:00", "crawled": "2018-05-17T16:52:42.000+03:00", "highlightTitle": ""}